Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors

Lau, Sally; Fares, Aline Fusco; Le, Lisa W.; Mackay, Kate M.; Soberano, Spencer; Chan, Sze Wah Samuel; Smith, Elliot Charles; Ryan, Malcolm; Tsao, Ming Sound; Bradbury, Penelope Ann; Pal, Prodipto; Shepherd, Frances A.; Liu, Geoffrey; Leighl, Natasha B.; Sacher, Adrian G.

doi:10.1016/j.cllc.2020.12.015

Cited by 51 publications

(46 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent paper, PDL1 expression was found to be higher in EGFR T790M positive after progression on Osimertinib: 5/10 had PD-L1 expression > 1% after progression vs. 0/10 at baseline [77]. Among other EGFR mutations, exon 20 insertions were associated with a higher frequency of PD-L1 expression [78,79].…”

Section: Pdl1 Expression In Nsclc With Actionable Oncogenic Driver Mutationmentioning

confidence: 99%

“…In the latter series, TMB was ≤5 Mut/Mb in all 13 cases. Recently, two more studies reported data on 13 and 21 HER2-mutated NSCLC patients, respectively, showing that 3/13 had a PD-L1 expression > 50% [79] and 4/21 tumors a PD-L1 expression > 1% [78].…”

Section: Pdl1 Expression In Nsclc With Actionable Oncogenic Driver Mutationmentioning

confidence: 99%

“…Two other retrospective studies also reported ORR in exon 20 EGFR-mutated NSCLC patients treated with anti-PD1/PD-L1 immunotherapy. In these studies 3/6 and 2/9 EGFR-Ex20ins patients exhibited a tumor response [78,79].…”

Section: Clinical Data On Anti-pd1/pd-l1 Efficacy In Nsclc With Actionable Oncogenic Driver Alterationsmentioning

confidence: 99%

See 2 more Smart Citations

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

Dantoing

Piton

Salaün

et al. 2021

IJMS

View full text Add to dashboard Cite

Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on PD-L1 expression by tumor cells and/or tumor mutational burden. However, mutations in oncogenic drivers such as EGFR, ALK, BRAF, or MET modify the immune tumor microenvironment and may promote anti-PD1/PD-L1 resistance. In this review, we discuss the molecular mechanisms associated with these mutations, which shape the immune tumor microenvironment and may impede anti-PD1/PD-L1 efficacy. We provide an overview of the current clinical data on anti-PD1/PD-L1 efficacy in NSCLC with oncogenic driver mutation.

show abstract

Section: Pdl1 Expression In Nsclc With Actionable Oncogenic Driver Mutationmentioning

confidence: 99%

Section: Pdl1 Expression In Nsclc With Actionable Oncogenic Driver Mutationmentioning

confidence: 99%

See 1 more Smart Citation

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

Dantoing

Piton

Salaün

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Masuda et al reported that PD-L1 expression is EGFR-mutated NSCLCs was 60% (9). Regarding EGFR exon 20 insertion mutations, several studies have reported on the antitumor effect of ICI therapy (10,11). Interestingly, the subtypes of EGFR mutation and the PD-L1 expression differed between left and right upper tumors; in addition, the There are no generally recognized guidelines for MPLC, although some diagnostic criteria are widely used in clinical investigations (12)(13)(14).…”

Section: Discussionmentioning

confidence: 99%

Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

A 78-year-old woman with multiple lung nodules, epithelial growth factor receptor (EGFR) exon 20 insertion mutations, and diagnosed with advanced lung adenocarcinoma (cT4N3M1a, stage IVA), was referred to our hospital. She received immune checkpoint inhibitor (ICI) therapy. The therapy showed remarkable antitumor effects; only a single nodule remained in the right upper lobe. The nodule was diagnosed as adenocarcinoma through a biopsy. We subsequently performed right upper lobectomy for multiple primary lung cancer (MPLC). The surgical specimen contained EGFR exon 19 deletion mutations and not exon 20 insertion mutations.

show abstract

“…Therefore, the NSCLC is treated based on the oncogene mutations [ 65 , 66 , 67 ]. Many EGFR inhibitors are available in the market to treat NSCLC with common mutations [ 9 , 10 , 11 , 12 , 13 , 14 , 68 ]. The EGFRex20ins mutation is considered an uncommon mutation and has also been acknowledged as a separate subclass of EGFR mutations [ 69 ].…”

Section: Expert Opinionmentioning

confidence: 99%

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions

Imran

Khan²,

Alshammari

et al. 2021

Biomedicines

View full text Add to dashboard Cite

The majority of lung cancers are non-small-cell lung cancer (NSCLC) having a low survival rate. Recent studies have indicated the involvement of epidermal growth factor receptor (EGFR) oncogene mutations like EGFR exon 20 insertions (EGFRex20ins) mutation among NSCLC patients. The response of patients of NSCLC with the EGFRex20ins mutation to the currently available EGFR inhibitor is negligible. Mobocertinib is the first oral treatment that has been approved by the USFDA, on 15 September 2021, to treat NSCLC with the EGFRex20ins mutation. This patent review discusses the inventions and patent literature of mobocertinib that will help the scientific community to develop additional and improved inventions related to mobocertinib. The structure of mobocertinib was first reported in 2015. Therefore, this article covered the patents/patent applications related to mobocertinib from 2015 to 25 October 2021. The patent search revealed 27 patents/patent applications related to compound, method of treatment, salt, polymorph, process, composition, and drug combinations of mobocertinib. The authors foresee an exciting prospect for developing a treatment for NSCLC with EGFRex20ins mutation, and other cancers employing a combination of mobocertinib with other approved anticancer agents. The inventions related to novel dosage forms, processes, and intermediates used in the synthesis of mobocertinib are also anticipated.

show abstract

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors

Cited by 51 publications

References 18 publications

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions

Contact Info

Product

Resources

About